OncoRef BRCA1/2®

In one simple analysis OncoRef BRCA1/2® includes complete sequencing via NGS and the detection of large deletions and duplications of genes BRCA1/2.

This allows us to provide results which are conclusive, rapid and reliable.

RefLab Guarantee

- **Pre and post test genetic advice**
- **Fast and reliable test results**
- **Maximum diagnostic efficiency and clinical utility**
- **The highest quality in all of our testing**

OncoRef BRCA1/2® studies the BRCA1/2 genes in order to evaluate the patients' risk of developing breast cancer.

- Test code: 12712
- Sample: 5 mL EDTA blood
- Required: informed consent, clinical history and family history

REFERENCE LABORATORY GENETICS

C/ Pablo Iglesias, 57
08908 Hospitalet de Llobregat
Barcelona · (+34) 932 593 700
www.referencelaboratory.es

mama.ENT1118

REFERENCE LABORATORY GENETICS

OncoRef BRCA1/2®

Susceptibility to hereditary breast cancer

The importance in diagnosing hereditary breast cancer

Breast cancer is the most common cancer in women, representing 29% of all oncological illnesses.

Approximately 5-10% of cases of breast cancer are hereditary1.

5-10%
of hereditary cases

BRCA1/2 genes contain more than 25% of the genetic variants responsible for the development of hereditary breast cancer.

25%
of the pathogenic gene variant are found in the BRCA1/2 gene

Genetic study of hereditary cancer is essential to ensure the correct treatment, diagnosis and care of the patient. What's more it's vitally important for other family members, who could also show a positive test result.

Susceptibility to breast cancer and BRCA1/2 genes

Patients who show the pathogenic gene variant in BRCA1/2 genes are at greater risk of developing breast cancer throughout their lives. More specifically, 60% in cases of BRCA1 and 50% in cases of BRCA2.

Risk of having breast cancer throughout their lives (%)



Advantages of OncoRef BRCA1/2®

Before the identification of the pathogenic gene variant in BRCA1/2 genes, we can implement preventative measures in patients diagnosed with breast or ovarian cancer, as well as family members who show the gene variant.

When to carry out a genetic study for hereditary breast cancer

High risk pathological-clinical criteria of hereditary breast cancer and ovarian cancer:

# cases of cancer in the family	Pathological-clinical criteria
1	• Breast cancer and ovarian cancer in the same person • Breast cancer <35 years • Bilateral breast cancer, 1º diagnosis <40 years • Triple negative breast cancer <50 years • High grade papillary serous ovarian carcinoma • Breast cancer in male's family
2	• Bilateral breast cancer + breast cancer diagnosed <50 years • Breast cancer + ovarian cancer • 2 breast cancer diagnosis <50 years
3	• ≥3 cases of breast cancer and/or ovarian cancer